Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations.

Bill, Ruben; Faquin, William C; Pai, Sara I (2023). Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations. Head and neck pathology, 17(4), pp. 969-975. Springer 10.1007/s12105-023-01590-6

Text s12105-023-01590-6.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB)

Immune checkpoint inhibitors have improved the outcome of patients diagnosed with inoperable recurrent or metastatic head and neck squamous cell carcinoma. However, as only a subset of head and neck cancer patients benefit from this treatment, biomarkers predicting treatment response help guide physicians in their clinical decision-making. PD-L1 expression assessed by immunohistochemistry is the single most clinically relevant biomarker predicting response to PD-1-blocking antibodies. Here, we discuss in which clinical context assessment of PD-L1 expression is instrumental for the choice of therapy, how pathologists score it, and how it affects the approval of anti-PD-1 antibodies. Furthermore, we discuss the heterogeneity of PD-L1 expression and review technical aspects of determining this prominent biomarker-knowledge that might influence clinical decision-making.

Interest & Impact

Downloads

0 since deposited on 07 Nov 2023
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item